devinitorg/iati-policy-markers huggingface dataset:
Fleming Fund The Fleming Fund is a £265m commitment by the UK Government to support low- and middle-income countries to tackle antimicrobial resistance (AMR) through improving surveillance capacity. Information about individual Fleming Fund projects and contracts can be found under the "child activities" linked to this activity. The Fleming Fund aims to: 1. support the development of National Action Plans for AMR; 2. develop and support the implementation of protocols and guidance for AMR surveillance and antimicrobial use; 3. build sustainable laboratory capacity for AMR sensitivity testing and diagnosis; 4. build sustainable drug resistance surveillance capacity and networks; 5. enable the sharing of drug resistance data locally, regionally and nationally; 6. facilitate the increased use of drug resistance data to monitor and address resistance as it evolves; and 7. advocate for the application of data to promote the rationale use of antimicrobials for human health, animal health and agriculture. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
International Health Regulations (IHR) Strengthening project The DHSC ODA-funded International Health Regulations Strengthening Project (IHR-S) provides peer to peer technical expertise through the UK Health Security Agency (UKHSA) to support public health partners to prepare, prevent, detect and respond to global health threats and increase compliance with the WHO International Health Regulations (IHR 2005). Compliance with IHR (2005) is fundamental as infectious disease outbreaks are expected to become more frequent in the future and preparedness is necessary to reduce health threats both internationally and within the UK. Lack of compliance to meet IHR (2005) requirements places countries under greater risk from disease outbreaks and other health emergencies, and has potentially wider implications on a global scale, as evidenced by the spread of Covid-19. IHR (2005) includes 13 technical areas such as surveillance, laboratories and points of entry as focal points to support countries to prevent, detect and respond to health threats. The IHR Strengthening Project has three key aims: to build technical capability, to strengthen leadership, systems and workforces, as well as to develop sustainable public health systems. IHR-S works bilaterally with four priority partner countries and three regions [including Nigeria, Pakistan, Ethiopia, Zambia, Africa (primarily through Africa CDC), the Eastern Mediterranean and Indo Pacific regions]. Over the course of this project the UK will work closely with the World Health Organization (WHO) to help it fulfil its leadership role in implementing the IHR and in responding to global public health emergencies. The project will work intimately with national governments, development partners and with regional and sub-regional agencies to deliver its support. This support will be coordinated with support from other donors, ensuring it adds value and is sustainable, identifies and responds to gaps, complements support from others and aligns behind nationally identified priorities. Implementation of UK support will be led by Public Health England, but may include contracting and working through UN agencies where appropriate and where this will maximise value for money.
Fleming Fund - Multilateral Grant to Food and Agriculture Organisation (FAO) Contribution to the Food and Agriculture Organisation (FAO) to increase public and political awareness of antimicrobial resistance (AMR) and support countries with AMR National Action Plans. The objectives of the Fleming Fund grant with FAO are to: 1. support development and implementation of AMR National Action Plans in 12 low- and middle-income countries (LMICs) in sub-Saharan Africa and South and South-east Asia; 2. strengthen regulatory frameworks; 3. increase societal awareness and understanding of AMR; 4. develop good practices in food and agriculture sectors, and ensure these are able to be implemented in target countries; and 5. strengthen the coordination across WHO, FAO and OIE in supporting the One Health agenda globally, and more specifically in LMICs. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund – Multilateral Grant to World Health Organization (WHO) Contribution to the World Health Organization (WHO) to support countries with antimicrobial resistance (AMR) National Action Plans and development of global protocols for collection of AMR data. The objectives of the Fleming Fund grant with WHO are to: 1. support countries to develop National Action Plans aligned with our regional focus in Sub-Saharan Africa, South and South-East Asia; 2. develop a One Health surveillance protocol on antimicrobial resistance focused on Escherichia coli (E. coli); 3. develop, pilot and roll out methods for antibiotic consumption and use monitoring; 4. Develop and support countries to implement of a new classification of antibiotics within the Essential Medicines List (EML) and the AWaRe categorisation to encourage rational use of antibiotics; 5. to support a deeper understanding of SF antimicrobials and their impact upon AMR; and 6. strengthen the coordination across WHO, FAO and OIE in supporting the One Health agenda globally, and more specifically in low- and middle-income countries (LMICs) Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
UK Vaccine Network - Vaccine Manufacturing Research Hubs Competition 2 The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is collaborating with EPSRC (a nondepartmental public body principally funded through the Science Budget by the Department of Science, Innovation and Technology) in running the Vaccine Manufacturing Research Hubs competition. EPSRC has considerable expertise in running competitions in this nature. The Vaccine Manufacturing Research Hubs competition will be open to all eligible research organisations that can demonstrate that their work would contribute towards Vaccine Manufacturing Research. Successful projects will be awarded a research grant from EPSRC, mostly funded by DHSC.
Fleming Fund - Country and Regional Grants and Fellowships Programme The Fleming Fund helps low- and middle-income countries to fight antimicrobial resistance. A management agent has been appointed to deliver: country grants 24 low- and middle-income countries, regional grants in West Africa, East and Southern Africa, South Asia and South East Asia, and a global fellowships programme. These initiatives aim to improve laboratory capacity and diagnosis as well as data and surveillance of antimicrobial resistance (AMR). Through the country and regional grants and the fellowships programme the Fleming Fund will: build laboratory capacity for diagnosis; collect data on drug resistance, drug quality, drug use and the burden of disease associated with AMR; enable the sharing of data relevant to AMR locally, regionally, and internationally; encourage the application of data to promote the rational use of antimicrobials; shape a sustainable system for AMR surveillance and data sharing; and increase national leadership in addressing AMR. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
UK Vaccine Network - Vaccines for epidemic diseases: readiness for clinical development and regulatory submission competition The Project is a Small Business Research Initiative (SBRI), Official Development Assistance (ODA) competition funded by the Department of Health and Social Care (DHSC). The aim of the competition is to further invest in vaccines and vaccine technologies to address the 12 priority diseases (including Disease X) identified by the UK Vaccine Network. Proposals can address any part of the pre-clinical, non-clinical, manufacturing, or clinical pathway, within a 1-year time frame, making technology ready to be progressed further along the developmental pathway. This is a managed programme on behalf of DHSC. UKRI-Innovate UK are providing a fully managed end to end service. The call goes live on 4th October 2021. The SBRI contracts are required to be in place and live by 31 March 2022. Beneficiary Projects funded through this competition are required to primarily benefit ODA eligible countries, as per ODA policy.
Fleming Fund - Civil society engagement through South Centre grant Through a grant to the South Centre the Fleming Fund is seeking to increase understanding of the challenges around antimicrobial resistance (AMR) and advocate for action among governments, civil society organisations and networks in low- and middle-income countries (LMICs). The grant to the South Centre will aim to 1. support positive developments in global processes of AMR and commitments to actions on addressing AMR; 2. assist developing countries to participate positively in the global processes on AMR and to have a sense of ownership of this agenda; 3. build the knowledge base and capacity of LMICs to understand the nature and seriousness of the AMR crisis and to take policy measures and actions nationally to address this crisis; and 4. strengthen the capability of civil society groups to build awareness and take actions on AMR issues. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Accelerating Antibacterial Innovation with CARB-X Through the Global AMR Innovation Fund (GAMRIF), the UK Department of Health and Social Care (DHSC) has invested £20 million over three years in Boston University’s Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), which is a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This contribution will invest in high-value, innovative research to accelerate the development of products to reduce the harm from drug-resistant infections. The aim of this project is to invest in high-value, innovative research to accelerate the development of products up to and including Phase I to reduce the harm to human health, welfare and economic growth from drug-resistant infections. In particular, the programme will focus on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in low- and middle-income countries (LMICs). Projects funded through GAMRIF will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
UK Public Health Rapid Support Team - Research "Created in 2016, the UK-PHRST is the primary arm of Her Majesty’s Government to provide and coordinate the UK’s public health response to outbreaks in LMICs. The UK-PHRST is a unique collaboration between Public Health England and the London School of Hygiene and Tropical Medicine with input from a number of academic partners. The UK-PHRST’s remit covers outbreak response, research, and capacity building, as components of its integrated triple mandate: • Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance (ODA), with the aim of stopping a public health threat from becoming a broader health emergency • Conduct research to generate an evidence base for best practice in epidemic preparedness and response • Build capacity for improved and rapid national response to disease outbreaks in LMICs and contribute to supporting implementation of IHR at the request of national governments or international stakeholders such as WHO. The UK-PHRST rapidly deploys a standing team of multidisciplinary public health professionals and researchers as required in countries that are a priority for the UK’s ODA programme. The UK-PHRST full-time Core Deployable Team consists of specialists in epidemiology, laboratory microbiology, infection prevention and control, clinical case management and clinical research, social science, data management and logistical support who are available to deploy within 48 of an approved request. Reservists and Field Epidemiology Training Programme (FETP) Fellows complement this team, providing surge capacity and specialist expertise when needed. The UK-PHRST is financed through UK Official Development Assistance (ODA) funding through the Department of Health and Social Care. The UK-PHRST Director is the accountable person to the UK Government, through PHE, for delivery of the UK-PHRST objectives." The UK Public Health Rapid Support Team (UK-PHRST) has the following main objectives: 1) Within ODA eligible countries to support the rapid investigation and response to disease outbreaks at source, with the aim of stopping a public health threat becoming a health emergency. 2) Conduct rigorous research to aid epidemic preparedness and response and improve future response. 3) Generate an evidence base for best practice in disease outbreak interventions within ODA eligible countries. 4) Train a cadre of public health reservists for the UK-PHRST who can be rapidly deployed to respond to disease outbreaks. 5) Build capacity in-country for an improved and rapid national response to disease outbreaks and contribute to supporting implementation of the International Health Regulations (IHR).
UK Vaccine Network - MRC/BBSRC Intramural Centre Vaccine Development Projects The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the global fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential in low and middle income countries (LMICs) for which the development of Vaccine Products is a priority. The Department of Health and Social Care collaborated with the Biotechnology and Biological Sciences Research Council and the Medical Research Council, both arms' length bodies of the Department of Business, Energy and Industrial Strategy, in running the 2016 competition which aims to support vaccine research to tackle UKVN-identified priority pathogens. This competition was wholly funded by Official Development Assistance and therefore projects must be primarily for the benefit of LMICs. The successful projects are being managed by the National Institute for Health Research. The Department of Health and Social Care made around £12 million available to fund six successful projects. This funding supports six projects seeking to develop candidate vaccines and vaccine platform technologies at late preclinical and early clinical stages against pathogens with epidemic potential in low and middle income countries. The UK Vaccine Network has identified 12 pathogens as a priority: Chikungunya, Crimean-Congo Haemorrhagic Fever, Ebola, Hantavirus, Lassa, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever, Rift Valley Fever and Zika. The aim of this funding is to progress the development of vaccines for these priority diseases, ultimately to support an effective and rapid response during future outbreaks of disease. Populations of the low and middle income countries where outbreaks of the UK Vaccine Network 12 priority pathogens occur.
New antibiotic treatments with Global Antibiotic Research & Development Partnership (GARDP) The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organisation developing new treatments for drug-resistant infections that pose the greatest threat to health and aims to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. GARDP addresses the most urgent threats to public health, particularly in low and middle-income countries (LMICs), by developing treatments for sepsis in children and new-borns, serious bacterial infections in adults, and sexually transmitted infections. GARDP bridges the gap between innovation and access by focusing on developing candidates in late-stage clinical development, and already available antibiotics, as treatments for drug resistant infections. The UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP for the development and delivery of new treatments for drug-resistant infections across the following three programmes: • Serious bacterial infections (SBIs) • Children’s antibiotics (Neonatal sepsis and paediatric development) • Sexually transmitted infections (STIs), including the novel antibiotic zoliflodacin against drug-resistant gonorrhoea
UK Vaccine Network - Vaccine development for diseases with epidemic potential The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. DHSC is engaging Innovate UK (an Executive Non-Departmental Public Body established by the Higher Education and Research Act 2017) to run the Vaccine development for diseases with epidemic potential competition. Innovate UK are responsible for the delivery and management of this work on behalf of DHSC. DHSC is making up to £25,000,000 (twenty-five million pounds) available to Innovate UK under the provisions of the International Development Act of 2002 to run the Vaccine development for diseases with epidemic potential competition and fund the Successful Project(s).
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Tackling Antimicrobial Resistance in Colombia via diagnostic uptake in pig farming ICARS (International Centre for Antimicrobial Resistance Solutions) is an international organisation created by the Danish government to tackle the barriers to successfully addressing AMR. The multi-funder arrangement offers risk-sharing as well as allowing DHSC to leverage co-funding. This partnership will allow DHSC to benefit from the existing relationships between ICARS and stakeholders in Colombia, and perhaps wider Latin America (a region where GAMRIF-supported innovation may have significant benefit if successful). DHSC and ICARS (International Centre for Antimicrobial Resistance Solutions) are undertaking a pilot partnership which will identify challenges and successes in the uptake of a novel, subsidised diagnostic platform model available to the pig farming industry in Colombia. This will support increased diagnosis, and therefore reduce inappropriate antimicrobial use. This project is managed on behalf of GAMRIF by the International Centre for Antimicrobial Resistance Solutions (ICARS) via Porkcolombia with support from the Colombian Ministry of Agriculture and Rural Development, who ICARS already hold an existing relationship with. Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in AMR Diagnostic Tools with FIND FIND is a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support FIND’s work to enhance the impact of diagnostic tools for antimicrobial resistance (AMR), to support improved AMR surveillance and antibiotic stewardship. This work has two areas of focus: 1) to develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access of data; and 2) to develop a new diagnostic technologies for drug-resistant gonorrhea, which will enable improved diagnosis and therefore use of new antibiotics. Projects funded through GAMRIF will primarily benefit people in low- and middle-income countries, where the burden of drug-resistant infection is greater.
Fleming Fund - FAO Country Grants (Sierra Leone Animal Health) Country grant which is being delivered by Food and Agriculture Organization of the United Nations (FAO). This grant is managed by the Fleming Fund management agent as part of the wider portfolio of country, regional and fellowship grants. However, as the grant is delivered by FAO the grant has been signed directly with the UK Department of Health and Social Care.
UK Vaccine Network - Future Vaccine Manufacturing Research Hub Competition The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the global fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential in low and middle income countries (LMICs) for which the development of Vaccine Products is a priority. The UKVN also advised that research to improve vaccine manufacturing should be a priority. The Department of Health and Social Care collaborated with the Engineering and Physical Sciences Research Council (EPSRC) (a non-departmental public body principally funded through the Science Budget by the Department of Business, Energy and Industrial Strategy) to run the Future Vaccine Manufacturing Research Hub competition. The competition was open to all eligible research organisations that could demonstrate that their work would contribute towards Vaccine Manufacturing Research specifically for the benefit of LMICs. £17million of funding was made available to EPSRC to fund two successful projects. This funding was provided under the provisions of the International Development Act 2002. This funding supports two projects which seek to: develop tools and technologies that allow for easier and quicker manufacturing of vaccines in emergencies, redesign existing vaccines to make them cheaper and easier to manufacture and easier to deliver in low and middle income countries (LMIC) settings and to provide bespoke support for researchers developing vaccines for diseases with epidemic potential, so that the vaccines they are developing are as rapid and cost-effective to manufacture as possible. The projects are expected to collaborate with LMIC researchers and industry to support this work. Populations of the low and middle income countries where outbreaks of the UK Vaccine Network 12 priority pathogens occur.
Fleming Fund - Independent Evaluation The Independent evaluation will assess how far the outputs of the portfolio of Fleming Fund country and regional grants, and the Fleming Fellowships will contribute to the outcomes and impact identified by the Department of Health and Social Care (DHSC). Six specific evaluation questions, were agreed during the inception phase for the evaluation. In answering the 6 set evaluation questions, the evaluation is intended to meet two objectives: 1. in 2019, the evaluation will generate learning to inform course correction and adaptation in the present phase of support; 2. in late 2020, the evaluation’s focus will shift to providing an independent summative judgement of the fund’s results and achievements. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.